Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses the utility of sipuleucel-T (Provenge) plus radium-223 (Xofigo) in nonmetastatic castration-resistant prostate cancer (CRPC).

Radium-223 is a bone-targeting radiopharmaceutical that emits an alpha particle, says Antonarakis.

As such, it is not likely to have efficacy in patients with nonmetastatic CRPC or rising prostate-specific antigen who do not have bone metastases, explains Antonarakis.

Sipuleucel-T is currently approved in metastatic CRPC. It is unknown whether sipuleucel-T and radium-223 can prevent bone metastases in patients with nonmetastatic CRPC. However, without a target, a drug like radium-223 may not be effective, concludes Antonarakis.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Cancer Centers

Partner

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.



Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC